Paragangliomas da Cabeça e Pescoço: A Experiência de um Centro Oncológico do Sul da Europa

Detalhes bibliográficos
Autor(a) principal: Castelhano, Luís
Data de Publicação: 2022
Outros Autores: Correia, Filipe, Donato, Sara, Ferreira, Lígia, Montalvão, Pedro, Magalhães, Miguel
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/17185
Resumo: Introduction: Paragangliomas are usually benign slow-growing tumors, but they are locally invasive and can cause significant morbidity. The aim of this study was to characterize the presenting symptoms, secretory status, genetics, imaging features, treatment modalities, post-treatment complications and survival of patients with head and neck paragangliomas treated at a single institution.Material and Methods: We retrospectively reviewed the clinical records of patients managed at our center between 1997 and 2020.Results: Seventy-three patients were included in the study, encompassing 89 head and neck paragangliomas. Forty-eight patients (65.8%) were female and 15 (20.5%) had multiple tumor sites (including 10 patients with multicentric benign paragangliomas and five with disseminated malignant disease). Regarding location, our series encompassed 40 temporal bone paragangliomas (44.9%), 24 carotid body paragangliomas (27%), 22 vagal paragangliomas (24.7%), two laryngeal paragangliomas (2.2%) and one sinonasal paraganglioma (1.1%). Excessive catecholamine secretion was detected in 11 patients (15.1%). Sixty-four patients (87.7%) underwent genetic testing. Of those, 24 (37.5%) exhibited pathogenic succinate dehydrogenase complex germline mutations. Regarding patients who presented with untreated disease, 45 patients (66.2%), encompassing 55 tumors, underwent surgery as primary treatment modality, 20 (29.4%; 23 tumors) were initially treated with radiotherapy and three patients (4.4%, encompassing three solitary tumors) were kept solely under watchful waiting. Five-year overall survival was 94.9% and disease-free survival was 31.9%.Conclusion: Head and neck paragangliomas are rare, slow-growing but locally aggressive tumors resulting in high morbidity but low mortality rates.
id RCAP_acb9afd87727bb8c5292af010fcae4f5
oai_identifier_str oai:ojs.www.actamedicaportuguesa.com:article/17185
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Paragangliomas da Cabeça e Pescoço: A Experiência de um Centro Oncológico do Sul da EuropaParagangliomas da Cabeça e Pescoço: A Experiência de um Centro Oncológico do Sul da EuropaCarotid Body TumorCranial Nerve NeoplasmsExtra-Adrenal ParagangliomaHead and Neck NeoplasmsParagangliomaNeoplasias de Cabeça e PescoçoNeoplasias dos Nervos CranianosParagangliomaParaganglioma ExtrassuprarrenalTumor do Corpo CarotídeoIntroduction: Paragangliomas are usually benign slow-growing tumors, but they are locally invasive and can cause significant morbidity. The aim of this study was to characterize the presenting symptoms, secretory status, genetics, imaging features, treatment modalities, post-treatment complications and survival of patients with head and neck paragangliomas treated at a single institution.Material and Methods: We retrospectively reviewed the clinical records of patients managed at our center between 1997 and 2020.Results: Seventy-three patients were included in the study, encompassing 89 head and neck paragangliomas. Forty-eight patients (65.8%) were female and 15 (20.5%) had multiple tumor sites (including 10 patients with multicentric benign paragangliomas and five with disseminated malignant disease). Regarding location, our series encompassed 40 temporal bone paragangliomas (44.9%), 24 carotid body paragangliomas (27%), 22 vagal paragangliomas (24.7%), two laryngeal paragangliomas (2.2%) and one sinonasal paraganglioma (1.1%). Excessive catecholamine secretion was detected in 11 patients (15.1%). Sixty-four patients (87.7%) underwent genetic testing. Of those, 24 (37.5%) exhibited pathogenic succinate dehydrogenase complex germline mutations. Regarding patients who presented with untreated disease, 45 patients (66.2%), encompassing 55 tumors, underwent surgery as primary treatment modality, 20 (29.4%; 23 tumors) were initially treated with radiotherapy and three patients (4.4%, encompassing three solitary tumors) were kept solely under watchful waiting. Five-year overall survival was 94.9% and disease-free survival was 31.9%.Conclusion: Head and neck paragangliomas are rare, slow-growing but locally aggressive tumors resulting in high morbidity but low mortality rates.Introdução: Os paragangliomas apresentam frequentemente um comportamento benigno e um crescimento indolente. Apesar disso, são localmente invasivos, podendo causar morbilidade significativa. O objetivo deste trabalho foi descrever as manifestações clínicas, atividade secretora, estudos genéticos e imagiológicos, modalidades terapêuticas, complicações e sobrevivência dos doentes com paragangliomas da cabeça e pescoço.Material e Métodos: Estudo retrospetivo dos doentes com paragangliomas da cabeça e pescoço observados num centro hospitalar terciário entre 1997 e 2020.Resultados: Foram incluídos no estudo 73 doentes, englobando 89 paragangliomas. Quarenta e oito doentes (65,8%) eram do sexo feminino e 15 (20,5%) apresentavam múltiplos focos tumorais (10 por multicentricidade e cinco por doença maligna disseminada). Foram incluídos 40 paragangliomas do osso temporal (44,9%), 24 tumores do corpo carotídeo (27%), 22 vagais (24,7%), dois laríngeos (2,2%) e um nasossinusal (1,1%). A secreção excessiva de catecolaminas foi detetada em 11 doentes (15,1%). Sessenta e quatro doentes (87,7%) foram alvo de teste genético. Desses, 24 (37,5%) exibiram mutações patogénicas do complexo succinato desidrogenase. Dos doentes com doença primária, 45 (66,2%; 55 tumores) foram submetidos a tratamento cirúrgico, 20 (29,4%; 23 tumores) a radioterapia e três (4,4%) ficaram sob vigilância. Aos cinco anos, a sobrevida global foi de 94,9% e a sobrevida livre de doença foi de 31,9%.Conclusão: Os paragangliomas da cabeça e pescoço são tumores raros, de crescimento lento, mas localmente agressivos que resultam em elevadas taxas de morbilidade, mas baixas taxas de mortalidade.Ordem dos Médicos2022-03-15info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/17185oai:ojs.www.actamedicaportuguesa.com:article/17185Acta Médica Portuguesa; Vol. 35 No. 11 (2022): November; 789-797Acta Médica Portuguesa; Vol. 35 N.º 11 (2022): Novembro; 789-7971646-07580870-399Xreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPenghttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/17185https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/17185/6577Direitos de Autor (c) 2022 Acta Médica Portuguesainfo:eu-repo/semantics/openAccessCastelhano, LuísCorreia, FilipeDonato, SaraFerreira, LígiaMontalvão, PedroMagalhães, Miguel2022-12-20T11:08:00Zoai:ojs.www.actamedicaportuguesa.com:article/17185Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T16:20:54.779615Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Paragangliomas da Cabeça e Pescoço: A Experiência de um Centro Oncológico do Sul da Europa
Paragangliomas da Cabeça e Pescoço: A Experiência de um Centro Oncológico do Sul da Europa
title Paragangliomas da Cabeça e Pescoço: A Experiência de um Centro Oncológico do Sul da Europa
spellingShingle Paragangliomas da Cabeça e Pescoço: A Experiência de um Centro Oncológico do Sul da Europa
Castelhano, Luís
Carotid Body Tumor
Cranial Nerve Neoplasms
Extra-Adrenal Paraganglioma
Head and Neck Neoplasms
Paraganglioma
Neoplasias de Cabeça e Pescoço
Neoplasias dos Nervos Cranianos
Paraganglioma
Paraganglioma Extrassuprarrenal
Tumor do Corpo Carotídeo
title_short Paragangliomas da Cabeça e Pescoço: A Experiência de um Centro Oncológico do Sul da Europa
title_full Paragangliomas da Cabeça e Pescoço: A Experiência de um Centro Oncológico do Sul da Europa
title_fullStr Paragangliomas da Cabeça e Pescoço: A Experiência de um Centro Oncológico do Sul da Europa
title_full_unstemmed Paragangliomas da Cabeça e Pescoço: A Experiência de um Centro Oncológico do Sul da Europa
title_sort Paragangliomas da Cabeça e Pescoço: A Experiência de um Centro Oncológico do Sul da Europa
author Castelhano, Luís
author_facet Castelhano, Luís
Correia, Filipe
Donato, Sara
Ferreira, Lígia
Montalvão, Pedro
Magalhães, Miguel
author_role author
author2 Correia, Filipe
Donato, Sara
Ferreira, Lígia
Montalvão, Pedro
Magalhães, Miguel
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv Castelhano, Luís
Correia, Filipe
Donato, Sara
Ferreira, Lígia
Montalvão, Pedro
Magalhães, Miguel
dc.subject.por.fl_str_mv Carotid Body Tumor
Cranial Nerve Neoplasms
Extra-Adrenal Paraganglioma
Head and Neck Neoplasms
Paraganglioma
Neoplasias de Cabeça e Pescoço
Neoplasias dos Nervos Cranianos
Paraganglioma
Paraganglioma Extrassuprarrenal
Tumor do Corpo Carotídeo
topic Carotid Body Tumor
Cranial Nerve Neoplasms
Extra-Adrenal Paraganglioma
Head and Neck Neoplasms
Paraganglioma
Neoplasias de Cabeça e Pescoço
Neoplasias dos Nervos Cranianos
Paraganglioma
Paraganglioma Extrassuprarrenal
Tumor do Corpo Carotídeo
description Introduction: Paragangliomas are usually benign slow-growing tumors, but they are locally invasive and can cause significant morbidity. The aim of this study was to characterize the presenting symptoms, secretory status, genetics, imaging features, treatment modalities, post-treatment complications and survival of patients with head and neck paragangliomas treated at a single institution.Material and Methods: We retrospectively reviewed the clinical records of patients managed at our center between 1997 and 2020.Results: Seventy-three patients were included in the study, encompassing 89 head and neck paragangliomas. Forty-eight patients (65.8%) were female and 15 (20.5%) had multiple tumor sites (including 10 patients with multicentric benign paragangliomas and five with disseminated malignant disease). Regarding location, our series encompassed 40 temporal bone paragangliomas (44.9%), 24 carotid body paragangliomas (27%), 22 vagal paragangliomas (24.7%), two laryngeal paragangliomas (2.2%) and one sinonasal paraganglioma (1.1%). Excessive catecholamine secretion was detected in 11 patients (15.1%). Sixty-four patients (87.7%) underwent genetic testing. Of those, 24 (37.5%) exhibited pathogenic succinate dehydrogenase complex germline mutations. Regarding patients who presented with untreated disease, 45 patients (66.2%), encompassing 55 tumors, underwent surgery as primary treatment modality, 20 (29.4%; 23 tumors) were initially treated with radiotherapy and three patients (4.4%, encompassing three solitary tumors) were kept solely under watchful waiting. Five-year overall survival was 94.9% and disease-free survival was 31.9%.Conclusion: Head and neck paragangliomas are rare, slow-growing but locally aggressive tumors resulting in high morbidity but low mortality rates.
publishDate 2022
dc.date.none.fl_str_mv 2022-03-15
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/17185
oai:ojs.www.actamedicaportuguesa.com:article/17185
url https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/17185
identifier_str_mv oai:ojs.www.actamedicaportuguesa.com:article/17185
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/17185
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/17185/6577
dc.rights.driver.fl_str_mv Direitos de Autor (c) 2022 Acta Médica Portuguesa
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Direitos de Autor (c) 2022 Acta Médica Portuguesa
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Ordem dos Médicos
publisher.none.fl_str_mv Ordem dos Médicos
dc.source.none.fl_str_mv Acta Médica Portuguesa; Vol. 35 No. 11 (2022): November; 789-797
Acta Médica Portuguesa; Vol. 35 N.º 11 (2022): Novembro; 789-797
1646-0758
0870-399X
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799130656615170048